Q4 2019 aTyr Pharma Inc Earnings Call
SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 – 29, 2020 at the San Diego Convention Center.
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications. “Many COVID-19 patients with severe disease experience serious, sometimes fatal, respiratory complications caused by an excessive inflammatory response in the lung, primarily driven by T-cells,” said Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The inflammatory lung injury related to COVID-19 may be similar to that of interstitial lung diseases, or ILDs, for which ATYR1923 is currently being investigated.”
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Limited (Pangu), together with the Hong Kong University of Science and Technology (HKUST), has been awarded a grant of approximately $750,000 to build a high-throughput platform for the development of bi-specific antibodies. The two-year project is being funded by the Hong Kong Government’s Innovation and Technology Commission (ITC) under the Partnership Research Program (PRP).
SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor to the company. “We would like to welcome Dr. Mercurio as a scientific advisor to our company and we look forward to his contributions as we continue to advance our understanding of NRP2 and its role in the development and metastatic progression of cancers,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.
Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company.
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Viking Global leader releases real-time trade in interstitial lung disease therapy provider Continue reading...
SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a publication highlighting the essential role that histidyl tRNA synthetase (HARS) plays in the modulation of immune cell engagement in a broad range of disease states, including interstitial lung diseases. The paper, titled “Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses,” was published in the journal Cellular and Molecular Immunology.
SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares of its common stock at a price to the public of $4.25 per share. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions. Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a poster session at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which is being held June 22 – 24, 2020. The abstract is available online and will be included in an online-only Proceedings supplement to the AACR journal Cancer Research following the AACR Virtual Annual Meeting II. The poster is expected to be available on the AACR website on June 22, 2020.
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 12, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that two abstracts originally accepted for presentation at the 2020 ATS International Conference will be published in the ATS journal, American Journal of Respiratory and Critical Care Medicine. One abstract characterizes the molecular basis for ATYR1923’s immunomodulatory properties, including its ability to specifically and selectively bind to NRP2, a target that has been implicated in a broad range of immune-mediated diseases.
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common stock have fully exercised their over-allotment option resulting in the issuance of an additional 635,294 shares of common stock. The option was granted in connection with the public offering of 4,235,294 shares of common stock at a public offering price of $4.25 per share, which closed on February 10, 2020.
SAN DIEGO, May 06, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
SAN DIEGO, March 19, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
NEW YORK, NY / ACCESSWIRE / April 13, 2020 / Levi & Korsinsky announces it has commenced an investigation of aTyr Pharma, Inc. (NASDAQ:LIFE) concerning possible breaches of fiduciary duty. To obtain additional ...
NEW YORK, NY / ACCESSWIRE / March 26, 2020 / aTyr Pharma, Inc. (NASDAQ:LIFE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 5:00 PM ...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?